NCI-H647 Xenograft Model Service for NSCLC

The NCI-H1155 xenograft model captures the distinctive biology of lung adenosquamous carcinoma—a hybrid NSCLC subtype exhibiting both glandular and squamous differentiation—derived from a patient with prior radiation exposure, offering a unique substrate for DNA-damage response and epigenetic therapy evaluation. Alfa Cytology provides a fully characterized NCI-H647 platform backed by authenticated cell banking, optimized implantation protocols, and comprehensive endpoint analysis to advance your preclinical programs in radiation-resistant and mixed-histology lung cancer.

Overview of NCI-H647 Xenograft Model for NSCLC

The NCI-H647 cell line was established in October 1983 by A.F. Gazdar and J.D. Minna at the National Cancer Institute from pleural effusion metastatic cells of a 56-year-old Caucasian male diagnosed with stage 3A lung adenosquamous carcinoma. This rare histological subtype combines malignant glandular and squamous components within the same tumor mass, presenting a more aggressive clinical course and distinct therapeutic vulnerabilities compared to pure adenocarcinoma or squamous cell carcinoma. The donor patient had received prior radiation therapy and was a non-smoker, factors that may have contributed to the genomic landscape of the derived line. Notably, NCI-H647 constitutively secretes the _β-subunit of human chorionic gonadotropin (hCG) along with tumor-associated antigens, providing a measurable serological biomarker that can be exploited for non-invasive tumor burden monitoring in vivo.

Fig 1. SLC7A11 knockdown efficiency in NSCLC cells was verified by qPCR, Western Blot, and IF. (Wan, Xiao‐dan, et al., 2025)

In immunodeficient hosts, NCI-H647 demonstrates reliable tumorigenicity with robust engraftment when 1×10⁶ to 1×10⁷ cells are implanted subcutaneously, typically with Matrigel support to enhance initial cell retention and vascularization. Tumors become palpable within 7–10 days and progress with consistent kinetics, maintaining the biphenotypic adenosquamous histology characterized by intermixed glandular formations and keratinizing squamous nests. The model has been extensively applied in investigations of DNA methyltransferase (DNMT) expression, radiation resistance mechanisms, and the tumor microenvironment, offering a versatile preclinical substrate for evaluating hypomethylating agents, DNA-damage response modulators, and combination strategies in a mixed-histology NSCLC context.

Cell Line Information: NCI-H647

The table below consolidates the essential biological, genetic, and operational characteristics of the NCI-H647 cell line to support informed experimental design and data interpretation.

Our Services

Alfa Cytology delivers a comprehensive NCI-H647 xenograft program encompassing authenticated cell banking, mycoplasma and sterility verification, tumor implantation, longitudinal monitoring, and multi-modal endpoint analysis. Our protocols—refined across numerous mixed-histology lung cancer studies—ensure consistent engraftment, reproducible tumor growth curves, and pharmacologically meaningful readouts that strengthen your preclinical development decisions.

Workflow of NCI-H647 Xenograft Model Construction

Construction of the NCI-H647 xenograft model at Alfa Cytology follows a regimented, IACUC-approved pipeline that prioritizes genetic authenticity, sterile technique, and reproducible tumor growth. Each operational phase is documented under GLP-aligned quality systems to ensure complete auditability from cell thaw to final dataset delivery.

1. Master Cell Bank Revival & Expansion: NCI-H647 cells are revived from authenticated, low-passage master stocks stored under liquid nitrogen and expanded in RPMI-1640 supplemented with 10% FBS. Each batch undergoes mycoplasma PCR screening, STR profiling confirmation against the published ATCC profile, and viability assessment prior to harvest.
2. Pre-Implantation Cell Preparation: Cultures in logarithmic growth phase are dissociated with trypsin-EDTA, neutralized with complete medium, and pelleted by centrifugation at 200×g for 5 minutes. The pellet is washed twice with sterile PBS to eliminate serum traces, then resuspended in ice-cold PBS at a concentration of 1×10⁸ cells/mL for a final inoculum of 1×10⁷ cells per 100 μL injection volume.
3. Matrigel Mixing & Injection Preparation: High-concentration, phenol-red-free Matrigel is thawed at 4°C overnight and maintained on ice. The cell suspension is mixed 1:1 with cold Matrigel immediately before injection to promote cell retention, angiogenesis, and standardized engraftment kinetics. The mixture is kept on ice at all times to prevent premature polymerization.
4. Subcutaneous Tumor Implantation: Six- to eight-week-old female athymic nude mice are acclimatized for a minimum of seven days. Under aseptic conditions, 200 μL of the cell-Matrigel suspension is injected subcutaneously into the right flank using a 26-gauge needle. Mice are monitored daily for general health and injection-site integrity.
5. Tumor Establishment & Cohort Randomization: Tumors are monitored by palpation beginning on day 5 post-implantation. Once tumors become palpable and reach a mean volume of 80–120 mm³—typically 10–14 days after injection—mice are stratified by tumor size and randomized into vehicle control and treatment cohorts (n = 8–10 per group).
6. Dosing, Monitoring & Endpoint Analysis: Test agents are administered according to protocol-specified routes (PO, IP, IV, or SC) and schedules. Tumor dimensions and body weights are recorded twice weekly; tumor volume is calculated as (width)² × length / 2. Studies conclude at a humane endpoint (typically 2,000 mm³ or 21–28 days post-treatment), at which point tumors are excised, weighed, and allocated for histopathology (H&E), immunohistochemistry (CK5/6, p40, TTF-1, Napsin A, Ki-67, CD31, TUNEL), and molecular profiling (qPCR, Western blot, RNA-seq). Serum is collected for hCGβ quantification where applicable.

Fig 2. NCI-H647 xenograft model construction workflow.

Case Study

In a recent preclinical evaluation, Alfa Cytology utilized the NCI-H647 subcutaneous xenograft to assess the efficacy of a novel DNA methyltransferase inhibitor in an adenosquamous NSCLC setting with post-radiation tumor biology. Following robust tumor engraftment in female athymic nude mice, animals were randomized into vehicle control and treatment arms (n = 8–10 per group) once mean tumor volume reached approximately 100 mm³. The test compound was administered via oral gavage on a daily schedule for 21 days. Longitudinal monitoring revealed a measurable reduction in tumor growth velocity in treated animals relative to vehicle controls, with the effect becoming apparent by the second week of dosing. At study termination, harvested tumors were subjected to comprehensive histopathological review and biomarker analysis, including dual staining for CK5/6 and TTF-1 to confirm adenosquamous lineage preservation, Ki-67 quantification to evaluate proliferative suppression, and TUNEL assay to assess apoptotic induction. Serum hCGβ levels were quantified as a surrogate pharmacodynamic marker. Body weight records remained stable across all cohorts, indicating an acceptable tolerability profile. Complete pharmacodynamic datasets, including individual tumor growth trajectories and histology images, are available for disclosure under a confidentiality agreement.

Why Choose Alfa Cytology?

Engaging Alfa Cytology for your NCI-H647 xenograft program provides access to a purpose-built infrastructure optimized for mixed-histology lung cancer preclinical research. Our service architecture combines scientific depth with operational agility to accelerate your compound evaluation timeline.

• Authenticated NCI-H647 master and working cell banks are maintained under liquid nitrogen with biannual STR confirmation against the ATCC reference profile and documented mycoplasma negativity, ensuring genetic stability across every study.
• Standardized implantation protocols with Matrigel support yield consistent tumor engraftment and predictable growth kinetics in adenosquamous carcinoma, enabling precise power calculations and efficient cohort sizing.
• Flexible study architectures accommodate single-agent, combination, dose-escalation, and epigenetic-targeting designs, with dosing routes and schedules tailored to your compound properties.
• On-site histopathology and IHC capabilities—including CK5/6, p40, TTF-1, Napsin A, Ki-67, CD31, and TUNEL—deliver rapid turnaround without external vendor coordination or sample custody interruptions.
• Secure client data portals provide real-time visibility into tumor measurements, body weights, and study milestones, with automated notifications at predefined protocol checkpoints.
• Each engagement is supported by a dedicated scientific project manager who coordinates weekly progress reports, interim data presentations, and adaptive protocol amendments aligned with your evolving research priorities.

Contact Us

If your research pipeline focuses on adenosquamous NSCLC—whether exploring epigenetic modulation, DNA-damage response targeting, or radiation sensitization in a mixed-histology context—Alfa Cytology offers the NCI-H647 xenograft expertise to advance your preclinical objectives with scientific rigor. Contact us today to discuss your study parameters, request a customized proposal, or arrange a consultation with our oncology model specialists. We are committed to converting your therapeutic hypothesis into robust, publication-ready preclinical evidence.

For research use only. Not intended for any clinical use.